These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12432241)
21. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056 [TBL] [Abstract][Full Text] [Related]
25. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Lessnick SL; Dacwag CS; Golub TR Cancer Cell; 2002 May; 1(4):393-401. PubMed ID: 12086853 [TBL] [Abstract][Full Text] [Related]
26. A molecular function map of Ewing's sarcoma. Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404 [TBL] [Abstract][Full Text] [Related]
27. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960 [TBL] [Abstract][Full Text] [Related]
28. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877 [TBL] [Abstract][Full Text] [Related]
29. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma. Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574 [TBL] [Abstract][Full Text] [Related]
30. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Bachmaier R; Aryee DN; Jug G; Kauer M; Kreppel M; Lee KA; Kovar H Oncogene; 2009 Mar; 28(9):1280-4. PubMed ID: 19151750 [TBL] [Abstract][Full Text] [Related]
31. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. Nakatani F; Tanaka K; Sakimura R; Matsumoto Y; Matsunobu T; Li X; Hanada M; Okada T; Iwamoto Y J Biol Chem; 2003 Apr; 278(17):15105-15. PubMed ID: 12560328 [TBL] [Abstract][Full Text] [Related]
32. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Zwerner JP; May WA Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway. Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300 [TBL] [Abstract][Full Text] [Related]
34. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423 [TBL] [Abstract][Full Text] [Related]
35. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Uren A; Toretsky JA Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028 [TBL] [Abstract][Full Text] [Related]
36. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. Ginsberg JP; de Alava E; Ladanyi M; Wexler LH; Kovar H; Paulussen M; Zoubek A; Dockhorn-Dworniczak B; Juergens H; Wunder JS; Andrulis IL; Malik R; Sorensen PH; Womer RB; Barr FG J Clin Oncol; 1999 Jun; 17(6):1809-14. PubMed ID: 10561219 [TBL] [Abstract][Full Text] [Related]
37. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186 [TBL] [Abstract][Full Text] [Related]
38. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Spahn L; Petermann R; Siligan C; Schmid JA; Aryee DN; Kovar H Cancer Res; 2002 Aug; 62(16):4583-7. PubMed ID: 12183411 [TBL] [Abstract][Full Text] [Related]
39. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Prieur A; Tirode F; Cohen P; Delattre O Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325 [TBL] [Abstract][Full Text] [Related]
40. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]